Loading…
Loading…
NAOV (NanoVibronix, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
TYLER, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced it has completed the transition of its NanoVibronix manufacturing operations from Israel to the United States, and consolidated its research and development operations in Tel Aviv, Israel, supporting the Company's broader initiative to reduce operating expenses and improve its cost structure. “Completing the transition of our NanoVibronix product line manufacturing to the United States marks the achievement of a major strategic operational initiative for the Company,” said Doron Besser, MD, CEO of ENvue Medical.
Technology supports the evolution of enteral access from blind procedures to real-time visualized placement Technology supports the evolution of enteral access from blind procedures to real-time visualized placement
Marc Waldman brings over 35 years of commercial leadership experience in the medical device industry with a proven track record of driving top-line growth Marc Waldman brings over 35 years of commercial leadership experience in the medical device industry with a proven track record of driving top-line growth
The program will integrate the Company's clinically validated NanoVibronix technology to improve comfort associated with indwelling nasogastric tubes The program will integrate the Company's clinically validated NanoVibronix technology to improve comfort associated with indwelling nasogastric tubes
Peak Medical, ENvue's Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® Kit Peak Medical, ENvue's Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® Kit
TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that it will change its corporate name from NanoVibronix, Inc. to ENvue Medical, Inc., effective December 12, 2025, to better reflect its new strategic direction and primary focus on its ENvue® feeding-tube placement system (“ENvue”). The Company's ticker for its common stock, listed on the Nasdaq Capit.
Nanovibronix (NASDAQ: NAOV - Get Free Report) and Veracyte (NASDAQ: VCYT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of recent ratings and
TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today issued a letter to shareholders, highlighting the Company's strategic vision, market opportunities and a rebranding initiative. Dear Shareholders, Since assuming the role of CEO in June 2025, our team has completed a comprehensive review of our operations, technologies and market opportunities. Throughout this pr.